Cara Therapeutics, Inc. CARA
At closeApr 15, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- -71.02%
- 1 year
- -79.19%
- Market cap
- 8.11M
- Revenue (ttm)
- 11.00M
- Shares out
- 54.86M
- Forward P/E
- -0.59
- YTD return
- -71.02%
- 1-year return
- -79.19%
- Volume
- 236.84K
- Open
- 4.80
- Previous close
- 5.32
- Day's range
- 5.28 – 5.52
- Beta
- 0.68
- Analysts
- Hold
- Price target
- 1.01 (-81.0%)
1Y -9.57 (-37.49%)
Key statistics
- Enterprise value
- 7.61M
- PEG ratio
- 0.00
- Price / sales
- 2.28
- Price / book
- 0.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -85.70%
- Free cash flow
- -47.50M
- Total cash
- 56.62M
- Total debt
- 47.16M
- Return on equity
- -184.32%
- Short % of float
- 2.00%
- 50-day average
- 0.29152
- 200-day average
- 0.46241
Analyst view
Consensus: hold
- Target (low)
- 1.00
- Target (mean)
- 1.01
- Target (high)
- 1.02
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.25 | -0.15 | +0.10 | +40.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | -0.37 | -0.08 | -27.59% |
| May 13, 2024 | Mar 1, 2024 | -0.38 | -0.56 | -0.18 | -47.37% |
| Mar 4, 2024 | Dec 1, 2023 | -0.57 | -0.59 | -0.02 | -3.51% |
| Nov 13, 2023 | Sep 1, 2023 | -0.53 | -0.52 | +0.01 | +1.89% |
| Aug 7, 2023 | Jun 1, 2023 | -0.56 | -0.58 | -0.02 | -3.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2024 | Canaccord Genuity | down | Buy | Hold |
| Jun 13, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 13, 2024 | Needham | down | Buy | Hold |
| May 23, 2024 | Needham | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | Needham | reit | Buy | Buy |
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- caratherapeutics.com
News
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics 
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics 
Cannabis Stock Gainers And Losers From April 11, 2025 
Cannabis Stock Gainers And Losers From April 10, 2025 
Cannabis Stock Gainers And Losers From April 8, 2025 
Marijuana Stock Movers For April 7, 2025 - Marijuana Stock Movers For April 4, 2025
Cannabis Stock Movers For April 3, 2025 
Bullish Sentiment Across The Cannabis Space - Check Full Movers For April 1, 2025 - Cannabis Stock Movers For March 31, 2025
Your note
Sign in to keep a note on CARA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOUDREAU HELEN M. | Director | Stock Award(Grant) | Jun 3, 2024 | 150,647 |
| GONCALVES JOANA | Officer | Sale | Apr 4, 2024 | 53,365 |
| IVES JEFFREY L | Director | Stock Award(Grant) | Jun 3, 2024 | 198,485 |
| MAYNARD RYAN D | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2024 | 13,500 |
| MENZAGHI FREDERIQUE | Officer | Stock Award(Grant) | Jan 31, 2024 | 167,247 |
| POSNER CHRISTOPHER | Chief Executive Officer | Sale | Nov 3, 2024 | 168,768 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.10% | 2,248,911 | 1.03M | Sep 29, 2024 |
| Chescapmanager LLC | 3.10% | 1,702,110 | 778.54K | Sep 29, 2024 |
| Farallon Capital Management LLC | 2.84% | 1,556,251 | 711.83K | Sep 29, 2024 |
| Disciplined Growth Investors, Inc. | 2.03% | 1,113,043 | 509.11K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.02% | 1,108,931 | 507.23K | Sep 29, 2024 |
| Two Sigma Advisers, LP | 1.58% | 866,300 | 396.25K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.47% | 1,354,313 | 619.46K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 645,753 | 295.37K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 261,602 | 119.66K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.41% | 224,141 | 102.52K | Aug 30, 2024 |
| Vanguard Health Care Index Fund | 0.30% | 165,236 | 75.58K | Aug 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.28% | 155,032 | 70.91K | Oct 30, 2024 |